Follow
Maurizio Scaltriti
Maurizio Scaltriti
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
NTRK fusion-positive cancers and TRK inhibitor therapy
E Cocco, M Scaltriti, A Drilon
Nature reviews Clinical oncology 15 (12), 731-747, 2018
11732018
The epidermal growth factor receptor pathway: a model for targeted therapy
M Scaltriti, J Baselga
Clinical cancer research 12 (18), 5268-5272, 2006
11602006
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ...
Cancer cell 19 (1), 58-71, 2011
10452011
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ...
Journal of the National Cancer Institute 99 (8), 628-638, 2007
10222007
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ...
Cancer research 68 (19), 8022-8030, 2008
9162008
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
7682018
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
6542018
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ...
Oncogene 30 (22), 2547-2557, 2011
5972011
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ...
Cancer discovery 2 (11), 1036-1047, 2012
5912012
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ...
Cancer research 68 (22), 9221-9230, 2008
5822008
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor
D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ...
Nature 518 (7538), 240-244, 2015
5582015
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ...
Cancer discovery 1 (3), 248-259, 2011
5112011
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M Scaltriti, C Verma, M Guzman, J Jimenez, JL Parra, K Pedersen, ...
Oncogene 28 (6), 803-814, 2009
4862009
Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial
BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ...
Journal of Clinical Oncology 36 (24), 2532, 2018
4672018
Targeted drug delivery strategies for precision medicines
MT Manzari, Y Shamay, H Kiguchi, N Rosen, M Scaltriti, DA Heller
Nature Reviews Materials 6 (4), 351-370, 2021
4102021
A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors
A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ...
Cancer discovery 7 (9), 963-972, 2017
3722017
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ...
Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011
3702011
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
EA Mittendorf, Y Wu, M Scaltriti, F Meric-Bernstam, KK Hunt, S Dawood, ...
Clinical Cancer Research 15 (23), 7381-7388, 2009
3532009
Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway
Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ...
Cancer cell 34 (6), 893-905. e8, 2018
3492018
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
C Marchiò, M Scaltriti, M Ladanyi, AJ Iafrate, F Bibeau, M Dietel, ...
Annals of Oncology 30 (9), 1417-1427, 2019
3392019
The system can't perform the operation now. Try again later.
Articles 1–20